Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli Lilly began marketing its rival product Mounjaro in the world's most populous nation.

Wegovy, a weight-loss injection containing semaglutide, has arrived in India, offering a new approach to combatting obesity and related metabolic issu

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite competitor Eli Lilly’s early mover advantage, and future competition from cheaper generics.